Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
MDA-MB-468 TNBC cells
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "MDA-MB-468 TNBC cells" in MCE Product Catalog:
2
2 Cited Publications
Target:
Research Areas:
BETd-246 is a BRD2/3/4 PROTAC degrader targeting the BET family. BETd-246 induces ubiquitination and proteasomal degradation of BRD2, BRD3 and BRD4 by recruiting the CUL4-RBX1-DDB1-CRBN E3 ubiquitin ligase complex; it also inhibits TRAT1 expression and depletes BET proteins. BETd-246 suppresses cancer cell proliferation and invasion, disrupts the cell cycle and induces apoptosis. BETd-246 is applicable to research related to triple-negative breast cancer and T-cell acute lymphoblastic leukemia .
Cat. No.: HY-138071
CAS No.: 83182-58-5
Synonyms: 8αTGH
Cat. No.: HY-W338764
CAS No.: 23749-58-8
Target:
Research Areas:
AHR agonist 3 is an aryl hydrocarbon receptor (AhR) agonist, that can induces cell cycle arrest or apoptosis via activation of tumor-suppressive transcriptional programs. AHR agonist 3 inhibits triple-negative breast cancer (TNBC) stem cell growth via AhR while exhibits minimal cytotoxicity against normal human primary cells and can be used for cancer research .
Cat. No.: HY-174828
ATR/PARP1-IN-1 is a potent ATR and PARP1 dual inhibitor with IC50s of 17.3 nM and 0.38 nM, respectively. ATR/PARP1-IN-1 effectively reduces cell viability, induces apoptosis and DNA damage. ATR/PARP1-IN-1 significantly impairs triple-negative breast cancer (TNBC) colony formation, migration, and invasion. ATR/PARP1-IN-1 suppresses tumor growth effectively in MDA-MB-468 xenografted mice, with no significant body weight change .
Cat. No.: HY-P10760
CAS No.: 1616592-31-4
Target:
Research Areas:
Cat. No.: HY-146452
CAS No.: 2408017-71-8
Anticancer agent 57 (compound 14) potently inhibits MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC50s of 6.43 ~ 8.00 μM. Anticancer agent 57 induces cell cycle arrest and significantly promotes apoptosis. Anticancer agent 57 inhibits tumor growth in nude mice xenografted with MADMB-231 cells. Anticancer agent 57 can be used for researching triple negative breast cancer (TNBC) .
Cat. No.: HY-179044
CAS No.: 3100092-62-1
MKK7-JNK activator 1 (Compound 10) is a MKK7-JNK pathway activator. MKK7-JNK activator 1 effectively inhibits the proliferation and migration of MDA-MB-468 cells, induces G2/M phase arrest and caspase -dependent apoptosis (independent of ROS production). MKK7-JNK activator 1 significantly increases the levels of p-MKK7 and p-JNK, but does not affect p-ERK or p-p38. MKK7-JNK activator 1 can be used for the study of triple-negative breast cancer (TNBC) .
Cat. No.: HY-168026
Target:
Research Areas:
CEP1347-VHL-02 is a selective MLK3 PROTAC degrader that mediates MLK3 degradation via the ubiquitin-proteasome system, with a DC50 of 50-300 nM. After degrading MLK3, CEP1347-VHL-02 inhibits downstream JNK signaling, induces G2/M phase arrest and apoptosis in cancer cells, and suppresses their clonogenic, migratory and 3D sphere-forming abilities. CEP1347-VHL-02 can be used for the research of triple-negative breast cancer .
Cat. No.: HY-168951
CAS No.: 3023189-40-1
(R)-SL18 is an annexin A3 (ANXA3) degrader with a Kd value of 1.15 μM for human ANXA3. (R)-SL18 induces ANXA3 degradation via the ubiquitination pathway, shows poor degradation selectivity among annexin family proteins, and its moderate ANXA3 binding affinity correlates with off-target effects. (R)-SL18 inhibits the proliferation, migration, invasion and colony formation of cancer cells. (R)-SL18 can be used in the research of triple-negative breast cancer .
Cat. No.: HY-188098
Research Areas:
ZSTK3341 is an aryl hydrocarbon receptor (AhR) and cytochrome P450 1A1 (CYP1A1) dependent cell growth inhibitor. ZSTK3341 exhibits growth inhibitory activity against cancer cells. ZSTK3341 can be used in the research of triple-negative breast cancer .
Cat. No.: HY-150946
CAS No.: 1453836-45-7
Research Areas:
CDK9 ligand 2 (compound CDK9 ligand 4) is a CDK9 ligand. CDK9 ligand 2 is used for the synthesis of PROTAC CDK9 degrader-14 (HY-133617) .
Cat. No.: HY-181999
Target:
PARP CDK Protease Activated Receptor (PAR) Wnt β-catenin Reactive Oxygen Species (ROS) DNA/RNA Synthesis
Research Areas:
PC8 is a selective dual inhibitor of PARP1/CDK6, with an IC50 of 0.126 μM for PARP1 and 0.197 μM for CDK6. PC8 does not alter PARP1 expression, but reduces the expression of its downstream target PAR. PC8 inhibits the canonical Wnt/β-catenin signaling pathway. PC8 induces intracellular ROS accumulation and exacerbates DNA damage. PC8 inhibits the proliferation of triple-negative breast cancer (TNBC) cells. PC8 can be used for the research of triple-negative breast cancer .
Cat. No.: HY-184969
Research Areas:
NUCC-0227579 is a VHL-recruiting PROTAC degrader targeting CD73, with a DC50 of 0.32 μM. NUCC-0227579 synergistically mediates CD73 degradation through the ubiquitin-proteasome pathway and the lysosomal pathway. NUCC-0227579 inhibits the conversion of AMP to adenosine, abrogates adenosine-mediated immunosuppression, upregulates the activities of the NF-κB and NFAT pathways, and enhances the secretion, activation and proliferation levels of IFN-γ and TNF-α. NUCC-0227579 downregulates NAD + synthesis in tumor cells, and inhibits the proliferation, migration and adhesion abilities of tumor cells under glutamine-deficient conditions. NUCC-0227579 significantly suppresses tumor growth in a humanized NSG mouse model of triple-negative breast cancer .
Cat. No.: HY-184396
Research Areas:
GR2-128 is a dual inhibitor targeting MLK3 and NAMPT with IC50 values of 84 nM and 14 nM, respectively. GR2-128 inhibits downstream JNK/c‑Jun signaling and reduces NAD + levels. GR2-128 exhibits antiproliferative and pro-apoptotic activities in triple-negative breast cancer cells without significant toxicity to normal cells. GR2-128 suppresses tumor growth, reduces macrophage and neutrophil infiltration, and increases tumor T-cell markers in a syngeneic mouse model, and can be used for triple-negative breast cancer research .
Cat. No.: HY-184307
Target:
Research Areas:
FAK1/2 Ligand-1 is a FAK1/FAK2 ligand with KD values of 2.9 μM and 2.5 μM for binding to FAK1 and FAK2, respectively. FAK1/2 Ligand-1 induces G2/M phase arrest, activates DNA damage-related signaling pathways, and reduces the phosphorylation level of CDK1. Antitumor agent-220 is applicable to the research of triple-negative breast cancer .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
